CoreSite Realty COR · NYSE
$340.88 -0.16% (-$0.53)
Summary
54 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 10 years in a row and pays out only 17% of profit.
- It earns 13 USD a year on every 100 USD of invested capital.
- Revenue grew by 10% a year over the last 3 years.
What to watch
- Out of every 100 USD of revenue, only 0.8 USD is left as net profit.
- For every 100 USD of shareholders' equity it carries 384 USD of debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.8 USD for 1 USD of yearly profit. Over the last five years it was 24.6 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 10% a year. For the next fiscal year analysts expect revenue to grow by 4.9%. Earnings per share fell by 0.3% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 96 USD
- Sales and administration 2.4 USD
- Taxes and other 0.5 USD
- Net profit 0.8 USD
Net profit, industry median (Medical - Distribution) 1.4 USD
Out of every 100 USD of revenue, 0.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.70%
- Paid out of profit
- 17%
- Raised in a row
- 10 years
You receive $2.40 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 33
- Hold 12
- Sell 1
Today's price within the analysts' price targets
The average target of $358.14 is 5.1% above today's price. 72% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Pharmaceutical Distribution 89%
- International Healthcare Solutions 9.4%
- Animal Health 1.8%
By region
- U.S. Healthcare Solutions 91%
- International Healthcare Solutions 9.4%
Pharmaceutical Distribution brings in 89% of revenue. International Healthcare Solutions grew fastest, by 28% a year.
Segments in detail